-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target

Benzinga·09/16/2026 12:23:50
Listen to the news
Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $11 price target.